Intralesional collagenaseClostridium histolyticumin the management of Peyronie's disease: current best practice

The use ofClostridium histolyticumcollagenase (CCH) has become increasingly widespread for the treatment of Peyronie's disease (PD) in recent years. Numerous trials have confirmed both its safety and efficacy in appropriately selected patients with this condition. The purpose of this review is to examine pivotal trials demonstrating the efficacy of CCH, revisit viable candidates for treatment with intralesional injection therapy, and provide a summary of injection technique and appropriate management of patients receiving this treatment at the time of therapy and in follow up.

Therapeutic advances in urology. 2018 Feb 08*** epublish ***

Daniel J Cwikla, Faysal A Yafi

Department of Urology, University of California Irvine, Orange, CA, USA., Department of Urology, University of California Irvine, 333 The City Blvd W, Suite 2100, Orange, CA 92868, USA.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.